- Home
- INO vs PFO Comparison
INO vs PFO Comparison
Compare INO & PFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INO | PFO |
|---|---|---|
| Founded | 1979 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 117.3M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | INO | PFO |
|---|---|---|
| Price | $1.64 | $8.90 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $6.75 | N/A |
| AVG Volume (30 Days) | ★ 695.8K | 32.8K |
| Earning Date | 03-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | ★ 54.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $42,220,086.00 | N/A |
| Revenue This Year | $24,407.60 | N/A |
| Revenue Next Year | $331.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.37 | N/A |
| 52 Week Low | $1.30 | $8.01 |
| 52 Week High | $2.86 | $9.90 |
Technical Indicators
Market Signals| Indicator | INO | PFO |
|---|---|---|
| Relative Strength Index (RSI) | 49.08 | 21.32 |
| Support Level | $1.48 | N/A |
| Resistance Level | $1.78 | $9.76 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 53.70 | 4.60 |
Price Performance
Historical ComparisonAbout INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.